Trial reportTrials2009
N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trial.
Trial report in Trials, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00808795 (Efficacy of N-Acetylcysteine in Prevention of Contrast-Induced Nephropathy After Cardiac Catheterization in Patients With Diabetes Mellitus and Chronic Kidney Disease), which is not on this map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy of N-Acetylcysteine in Prevention of Contrast-Induced Nephropathy After Cardiac Catheterization in Patients With Diabetes Mellitus and Chronic Kidney Disease: A Randomized Clinical Trial
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Effectiveness of contrast-associated acute kidney injury prevention methods; a systematic review and network meta-analysis.BMC nephrology · 2018Pooled it
- Acute kidney injury.BMJ clinical evidence · 2011Pooled it
- Intravenous magnesium sulfate: new method in prevention of contrast-induced nephropathy in primary percutaneous coronary intervention.International urology and nephrology · 2015Trial
- Efficacy of pentoxifylline in prevention of contrast-induced nephropathy in angioplasty patients.International urology and nephrology · 2012Trial
- Efficacy of vitamin E and N-acetylcysteine in the prevention of contrast induced kidney injury in patients with chronic kidney disease: a double blind, randomized controlled trial.Wiener klinische Wochenschrift · 2012Trial
- Physiological principles underlying the kidney targeting of renal nanomedicines.Nature reviews. Nephrology · 2024Review
- A Systematic Review of the Effect of N-Acetylcysteine on Serum Creatinine and Cystatin C Measurements.Kidney international reports · 2021Article
- Large animal models for translational research in acute kidney injury.Renal failure · 2020Review
- Contrast-induced nephropathy and oxidative stress: mechanistic insights for better interventional approaches.Journal of translational medicine · 2020Review
- Oral N-acetylcysteine for prophylaxis of contrast-induced nephropathy in patients following coronary angioplasty: A meta-analysis.Experimental and therapeutic medicine · 2017Article
- Effectiveness of N-Acetylcysteine for the Prevention of Contrast-Induced Nephropathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Journal of the American Heart Association · 2016Article
- Bridging translation for acute kidney injury with better preclinical modeling of human disease.American journal of physiology. Renal physiology · 2016Review
- Atorvastatin combining with probucol: a new way to reduce serum uric acid level during perioperative period of interventional procedure.TheScientificWorldJournal · 2014Article
- Prevention of contrast-induced AKI: a review of published trials and the design of the prevention of serious adverse events following angiography (PRESERVE) trial.Clinical journal of the American Society of Nephrology : CJASN · 2013Review
- Five years of Trials.Trials · 2011Article
- Evaluation of brain and kidney energy metabolism in an animal model of contrast-induced nephropathy.Metabolic brain disease · 2011Article
- Contrast-induced acute kidney injury: short- and long-term implications.Seminars in nephrology · 2011Review
- Prevention of Contrast-Induced Nephropathy (CIN) in Interventional Radiology Practice.Seminars in interventional radiology · 2010Article
- Article
- Renal Function following Fluorescein Angiography in Diabetic Patients with Chronic Kidney Disease.Journal of ophthalmic & vision researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with diabetes mellitus (DM) and chronic kidney disease (CKD) constitute to be a high-risk population for the development of contrast-induced nephropathy (CIN), in which the incidence of CIN is estimated to be as high as 50%. We performed this trial to assess the efficacy of N-acetylcysteine (NAC) in the prevention of this complication.
methodsIn a prospective, double-blind, placebo controlled, randomized clinical trial, we studied 90 patients undergoing elective diagnostic coronary angiography with DM and CKD (serum creatinine > or = 1.5 mg/dL for men and > or = 1.4 mg/dL for women). The patients were randomly assigned to receive either oral NAC (600 mg BID, starting 24 h before the procedure) or placebo, in adjunct to hydration. Serum creatinine was measured prior to and 48 h after coronary angiography. The primary end-point was the occurrence of CIN, defined as an increase in serum creatinine > or = 0.5 mg/dL (44.2 micromol/L) or > or = 25% above baseline at 48 h after exposure to contrast medium.
resultsComplete data on the outcomes were available on 87 patients, 45 of whom had received NAC. There were no significant differences between the NAC and placebo groups in baseline characteristics, amount of hydration, or type and volume of contrast used, except in gender (male/female, 20/25 and 34/11, respectively; P = 0.005) and the use of statins (62.2% and 37.8%, respectively; P = 0.034). CIN occurred in 5 out of 45 (11.1%) patients in the NAC group and 6 out of 42 (14.3%) patients in the placebo group (P = 0.656).
conclusionThere was no detectable benefit for the prophylactic administration of oral NAC over an aggressive hydration protocol in patients with DM and CKD.
trial registrationNCT00808795.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.